Gustaaf W van Imhoff
Overview
Explore the profile of Gustaaf W van Imhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chamuleau M, Stenner F, Chitu D, Novak U, Minnema M, Geerts P, et al.
Lancet Haematol
. 2023 Nov;
10(12):e966-e975.
PMID: 37922925
Background: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was...
2.
de Vries S, Schaapveld M, Janus C, Daniels L, Petersen E, van der Maazen R, et al.
J Natl Cancer Inst
. 2020 Dec;
113(6):760-769.
PMID: 33351090
Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. Methods: This multicenter cohort included 4919 HL patients, treated before age...
3.
Chamuleau M, Burggraaff C, Nijland M, Bakunina K, Mous R, Lugtenburg P, et al.
Haematologica
. 2020 Dec;
105(12):2805-2812.
PMID: 33256379
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without...
4.
Wulf G, Altmann B, Ziepert M, DAmore F, Held G, Greil R, et al.
Leukemia
. 2020 May;
35(1):143-155.
PMID: 32382083
PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial....
5.
Plattel W, Visser L, Diepstra A, Glaudemans A, Nijland M, van Meerten T, et al.
Br J Haematol
. 2020 Feb;
190(1):40-44.
PMID: 32106342
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim F-fluorodeoxyglucose positron-emission...
6.
Kok L, Bungener L, de Bock G, Biswana A, van der Wal G, van Imhoff G, et al.
Hum Cell
. 2019 Nov;
33(1):243-251.
PMID: 31732859
Moderate to severe chronic graft-versus-host disease (cGVHD) is associated with high morbidity, hospital dependency and poor quality of life. In this study, we analyzed a well-defined consecutive series of 98...
7.
Lugtenburg P, Zijlstra J, Doorduijn J, Bohmer L, Hoogendoorn M, Berenschot H, et al.
Br J Haematol
. 2019 Jul;
187(3):347-355.
PMID: 31290569
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab,...
8.
Rigter L, Schaapveld M, Janus C, Krol A, van der Maazen R, Roesink J, et al.
Cancer Med
. 2018 Dec;
8(1):190-199.
PMID: 30592184
Background: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs...
9.
Nijland M, Seitz A, Terpstra M, van Imhoff G, Kluin P, van Meerten T, et al.
Cancers (Basel)
. 2018 Nov;
10(11).
PMID: 30463380
Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using...
10.
Aukema S, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, et al.
Histopathology
. 2017 Jul;
71(6):960-971.
PMID: 28730642
Aims: Low-grade follicular lymphoma (FL) (grade 1/2, FL1/2) has an annual risk of transformation of ≈3%, which is associated with aberrations in CDKN2A/B, TP53, and MYC. As in diffuse large...